Alterity Therapeutics (ATHE) Restructuring Costs (2020)

Alterity Therapeutics (ATHE) recorded quarterly Restructuring Costs of -$1.6 million in Q2 2020.

Alterity Therapeutics (ATHE) Restructuring Costs (2020) Analysis & Trends

Alterity Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at -$1.6 million for Q2 2020.

In Q2 2020, Restructuring Costs changed N/A year-over-year to -$1.6 million; the TTM figure through Jun 2020 stood at -$1.6 million (changed N/A YoY), while the FY2020 annual figure was -$1.6 million, changed N/A from the prior year.
Restructuring Costs was -$1.6 million for Q2 2020 at Alterity Therapeutics.
In the past five years, Restructuring Costs ranged from a high of -$1.6 million in Q2 2020 to a low of -$1.6 million in Q2 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Regeneron Pharmaceuticals	63.59 Bn	54.83 Bn	3.31 Bn

Historic Data

Download Data

Date	Value
Jun 30, 2020	-1.55 Mn